Sirio Pharma eyes global R&D collaboration

China's CDMO plans to combine the expertise of its 100+ scientist based in Asia, Europe and the US

Sirio Pharma, the Chinese nutraceutical CDMO, has announced plans to implement a global collaboration to help customers bring innovative, safe and effective products quickly to market.

Headquartered in Guangdong, a coastal province in south-east Asia, Sirio specialises in gummies, softgels, tablets, capsules, powders, and oral liquids.

As part of the plan, Sirio’s 100+ scientists and industry experts, based in Asia, Europe and the United States, will combine research and development efforts to focus on proactive innovation.

Rui Yang, Sirio Pharma CSO, commented: “The industry demands products that are more natural and additive free, with consumer-friendly labelling and increased transparency. The challenge for brand owners is how to develop these products quickly without compromising on quality. Our global collaboration will be instrumental in helping our customers develop innovative products that conform with these trends"

For Yang, it is a big challenge for companies to improve existing formulations because "it requires a large and experienced in-house R&D team".

Sirio said the company has access to over 500 stock formulas, and its R&D specialists will explore novel combinations of ingredients, ensuring products are effective, shelf stable and great tasting.

Another key objective is to provide customers with more clean label options for their products such as natural flavours, colours and sweeteners and eco-friendly packaging solutions.

With this plan, Sirio seeks to empower customers from all markets to advance product R&D more rapidly and confidently launch new products faster. Great examples of this new collaborative effort at work include new products such as curcumin gummies and probiotic and collagen supplements.

“This collaboration is the natural evolution of our commitment to continuous improvement and forward thinking. The key in this industry is speed to market – being able to rapidly bring new products from concept to commercialisation. We take an extremely proactive approach to our new product development pipeline, planning up to three years in advance as to where consumer preferences are heading” commented Yang.

Sirio has a long history of developing new approaches and proactively innovating. The company launched Treerly Health, a premium nutraceutical consumer brand in China, which was acquired by Pfizer in 2016.

Companies